|
- Clinical efficacy and mechanisms of biologics for chronic . . .
We review CRSwNP clinical trial and real-world data on the effectiveness and safety of biologics, discuss their therapeutic mechanisms, assess outcomes of biologic therapy versus endoscopic sinus surgery, and discuss therapies in development and future directions (J Allergy Clin Immunol 2025;155:1401-10 )
- Efficacy and Safety of Biologics for Chronic Rhinosinusitis . . .
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs) With recent regulatory approvals, there has been a surge in real-w …
- Twice-Yearly Biologic Effective Against Nasal Polyps
Enrollment required a nasal polyp score of 5-8 and either 3 consecutive days of systemic steroid treatment in the past 2 years or any previous surgery for nasal polyps
- Dupilumab outperforms omalizumab in chronic rhinosinusitis . . .
Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, according to an abstract presented at European Academy of Allergy amp
- Unlocking Personalized Treatment for Chronic Nasal Polyps . . .
Although a chronic disease, CRSwNP can be managed with anti-inflammatory nasal steroids and surgery but some patients are unable to achieve disease control Recently, a new paradigm of treatment was approved for CRSwNP – biologic therapies
|
|
|